Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 4
Submit an article Journal homepage
88
Views
19
CrossRef citations to date
0
Altmetric
Review

Emerging trends in the pharmacotherapy of chronic pain

AN Nitu Finch University of Health Sciences/Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064-3095, USA. [email protected]
,
R Wallihan Finch University of Health Sciences/Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064-3095, USA. [email protected]
,
V Skljarevski Finch University of Health Sciences/Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064-3095, USA. [email protected]
&
NM Ramadan Finch University of Health Sciences/Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064-3095, USA. [email protected]
Pages 545-559 | Published online: 02 Mar 2005

Bibliography

  • CLARK JD: Chronic pain prevalence and analgesic prescribing in a general medical population.j Pain Symptom Manag. (2002) 23(2):131–137.
  • NIH GUIDE: Directions in Pain Research I. United States Government Printing Office, Washington DC (4 September 1998).
  • ROY R, MICHAEL T: A survey of chronic pain in an elderly population. Can. Fam. Physician (1986) 32:513–516.
  • HUBBARD RC, LAURENT AL, KUSS ME et al: A pharmacokinetic study of analgesic doses of parecoxib, a new cox-2 specific inhibitor, in healthy subjects. American Pain Society 19th Annual Meeting, Atlanta, GA, USA (2000) (Abstract 653).
  • KIVITZ A, EISEN G, ZHAO WW, BEVIRT T, RECKER DP: Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. I Fam. Pract. (2002) 51:6.
  • Gabapentin, lamotrigine, oxcarbazepine, topiramate, valdecoxib, venlafaxine and zileuton drug monographs. MOSBY'S DRUG CONSULT O Mosby, Inc. (2002).
  • BENSEN W, WEAVER A, ESPINOZA Let al.: Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (2002) 41:1008–1016.
  • DANIELS SE, TALWALKER S, TORRI S, SNABES MC, RECKER DP, VERBURG KM: Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet. Cynecol. (2002) 100(2):350–8.
  • RIENDEAU D, PERCIVAL MD, BRIDEAU C, et al: Etoricwdb (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Pharmacol Exp. The]: (2001) 296(2):558–66.
  • DAY R.: Another selective COX-2 inhibitor: More questions than answers? .1 Rheumatol. (2002) 29(8):1581–1583.
  • GOTTESDIENER K, SCHNITZER T, FISHER C et al.: Results of a randomized, dose-ranging trial of etoricwdb in patients with osteoarthritis. Rheumatology (Oxford) (2002) 41(9):1052–1061.
  • LEUNG AT, MALMSTROM K, GALLACHER AE et al.: Efficacy and tolerability profile of etoricwdb in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Carr: Med. Res. Opin. (2002) 18(2):49–58.
  • CURTIS SP, MALDONADO-COCCO J,LOSADA BR et al.: Treatment with etoricwdb (Mk-0663), a cox-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. Annual European Congress of Rheumatology: European League Against Rheumatism, Prague, Czech Republic (2001) (Abstract FRI0030).
  • COLLANTES E: A multinational randomized, controlled, clinical trial of etoricwdb in the treatment of rheumatoid arthritis. BMC Fam. Pract. (2002) 3(1):10.
  • MATSUMOTO AK, MELIAN A, MANDEL DR et al.: A randomized, controlled, clinical trial of etoricwdb in the treatment of rheumatoid arthritis. Rheumatol (2002) 29(8):1623–1630.
  • GEBA GP, PUOPOLO AD, BIRBARA C et al: Treatment of chronic low back pain (lbp) with etoricoxib, a new cyclo-oxygenase-2 inhibitor: a three-month placebo-controlled trial. American Pain Society Annual Meeting, Baltimore, MD, USA (2002) (Abstract 647).
  • REGINSTER J, BIAS P, BUCHNER A: First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-Lox, for the treatment of osteoarthritis. Annual European Congress of Rheumatology: European League Against Rheumatism, Stockholm, Sweden (2002) (Abstract THU0189).
  • ADIS R & D INSIGHT: Elan issues a further report on development pipeline: full analysis of ziconotide Phase III neuropathic pain data reported; first Phase II study reported on ziconotide in acute post-surgical pain. PR Newswire (15 December 1998).
  • MOORE A, DELLA CASA ALBERIGHI O, GITTON X, SLOAN V, GIMONA A: Responder rate of COX189 in osteoarthritis: a multi-national study. Annual European Congress of Rheumatology: European League Against Rheumatism, Stockholm, Sweden (2002) (Abstract THU0265).
  • RORDORF C, SCOTT G, BLOOD P: Treatment of healthy subjects with cox189, a cox-2 selective inhibitor; endoscopic evidence for lack of gastro-duodenal erosions compared to non-selective. Annual European Congress of Rheumatology: European League Against Rheumatism, Stockholm, Sweden (2002) (Abstract THU 0232).
  • CODREANU C: Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, cox189 compared with ibuprofen in osteoarthritis patients. Annual European Congress of Rheumatology: European League Against Rheumatism,Stockholm, Sweden (2002) (Abstract 226).
  • NOVARTIS: Data suggest that Prexige (lumiracoxib), a new COX-2 inhibitor, offers strong efficacy. Latest results additionally confirm Prexige is well-tolerated with gastrointestinal safety superior to NSAIDs. (2002) (Press release).
  • WEINBLATT ME, KREMER JM, COBLYN JS et al: Zileuton, a 5-lipooxygenase inhibitor in rheumatoid arthritis. J. Rheumatol (1992) 19:1537–1541.
  • KREMER JM, BRAND WEIN SR, 5-LIPOOXYGENASE STUDY GROUP: Effect of zileuton, a novel selective 5-lipooxygenase inhibitor in rheumatoid arthritis. Arthritic Rheum. (1994) 37\(Suppl. 341).
  • CHAPLAN SR, POGREL JW, YAKSH TL: Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. Pharmacol Exp. The]: (1994) 269(3):1117–1123.
  • MALMBERG AB, YAKSH TL: Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain (1995) 60(1):83–90.
  • PRESLEY R, CHARAPATA S, STAATS P et al.: Intrathecal ziconotide in the treatment of opioid-resistant pain: A Controlled Clinical Trial. American Pain Society 19th Annual Meeting, Atlanta, GA, USA (2000) (Abstract 628).
  • PENN RD, PAICE JA: Adverse effects associated with the intrathecal administration of ziconotide. Pain (2000) 85:291–296.
  • WALLACE M: Identification of an effective and well-tolerated dose range for ziconotide, a novel non-opioid intrathecal analgesic for chronic nonmalignant pain. American Pan) Society 20th Annual Meeting, Phoenix, AZ, USA (2001) (Abstract, poster 777).
  • LUTHER RR, SPERZEL DW, VALENTINO KL: Pharmacologic activity of snx-111, the first n-type, neuron specific, calcium channel blocker is demonstrated in man. J. Clin. Pharmacol (1994) 34:1014.
  • SIMPSON DM, OLNEY R, MCARTHUR JC et al: A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology (2000) 54:2115–2119.
  • VESTERGAARD K, ANDERSEN G, GOTTRUP H, KRISTENSEN BT, JENSEN TS: Lamotrigine for central poststroke pain a randomized controlled trial. Neurology (2001) 56:184–190.
  • JENSEN TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Ear: J. Pan) (2002) 6 (Suppl. A):61–68.
  • ZAKRZEWSKA JM, CHAUDHRY Z, NURMIKKO TJ, PATTON DW, MULLENS EL: Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain (1997) 73(2):223–230.
  • MCCLEANE G: 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pan) (1999) 83(1):105–107.
  • BEYDOUN A, D'SOUZAJ: Double-blind comparative trial of oxcarbazepine versus carbamazepine in new-onset trigeminal neuralgia. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 931).
  • BEYDOUN A, SCHMIDT D, D'SOUZA J: Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. American Pain Society 21st Annual Meeting, Baltimore, MD, USA (2002) (Abstract 749).
  • COHEN H, LAW-YONE B: Blowfish toxin: a new approach to pain management. Texas Pain Bulletin (April 2001).
  • KHOROMI S, PARADA S, CAHILL K, MAX MB: Topiramate in the treatment of chronic sciatica. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 919).
  • GILRON I, BOOHER SL, ROWAN JS, MAX MB: Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin. Neuropharmacol (2001) 24(2):109–112.
  • HAUGH MJ, CONNOR GS: Trigeminal Neuralgia: Pain relief in patients treated with the anticonvulsant topiramate. American Pan) Society 19th Annual Meeting, Atlanta, GA, USA (2000) (Abstracts 675).
  • TAYLOR CP, GEE NS, SU TZ et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. (1998) 29(3):233–249.
  • ROWBOTHAM M, HARDEN N, STACEY B et al.: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA (1998) 280(21):1837–1842.
  • RICE ASC, MATON 5, POSTHERPETIC NEURALGIA STUDY GROUP: Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain (2001) 94:215–224.
  • BACKONJA M, BEYDOUN A, EDWARDS KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus a randomized controlled trial. JAMA (1998) 280:1831–1836.
  • GORSON KC, SCHOTT C, HERMAN R et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J. Neurol Neurosurg. Psychiatry (1999) 66(2):251–252.
  • MORELLO CM, LECKBAND SG, STONER CP et al: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. (1999) 159(16):1931–1937.
  • FASSOULAKI A, PATRIS K, SARANTOPOULOS C, HOGAN Q: The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth. Analg. (2002) 95(4):985–991.
  • SELAK I: Pregabalin (Pfizer). Curc Opin. Investig. Drugs (2001) 2(6):828–834.
  • GLESSNER C, SHARMA U, IACOBELLIS D, MOORE J, LAMOREAUX L, POOLE RIVI: Pregabalin is efficacious for relief of painful diabetic neuropathy. American Pain Socieo, 20th Annual Meeting, Phoenix, AZ, USA (2001) (Abstract 769).
  • RICHTER R, DWORKIN RH, SHARMA U et al.: Pregabalin is effective in patients with painful diabetic neuropathy as evaluated in three clinical trials. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 1726).
  • CORBIN AE, REMMERS AE, LAMOREAUX L, YOUNG JP, POOLE RIVI: Pregabalin reduces pain in patients with postherpetic neuralgia (PHN). American Pain Socieo, 20th Annual Meeting, Phoenix, AZ, USA (2001) (Abstract 768).
  • CORBIN AE, YOUNG JP, LAMOREAUX L et al: Pregabalin reduces pain in patients with postherpetic neuralgia: supportive data from SF-mcgill pain questionnaire (SF-MPQ). American Pain Society 21st Annual Meeting, Baltimore, MD, USA (2002) (Abstract 785).
  • Pfizer's pregabalin significantly improves pain in fibromyalgia patients. Newswire (25 October 2002).
  • MARTIN SA, CORBIN AE, REMMERS AE et al.: Pregabalin improves sleep in patients with postherpetic neuralgia (PHN). American Pain Socieo, 20th Annual Meeting, Phoenix, AZ, USA (2001) (Abstract 775).
  • REMMERS AE, SHARMA U, LAMOREAUX L et al: Pregabalin treatment of patients with chronic low back pain. American Pain Socitv, 19th Annual Meeting, Atlanta, GA, USA (2000) (Abstracts 660).
  • BIALER M, JOHANNESSEN S, KUPFERBERG H et al: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34(1):1–41.
  • WOOLF CJ, BENETT GJ, DOHERTY M et al.: Towards a mechanism-based classification of pain? Pain (1998) 77:227–229.
  • WOOLF CJ, MAX M: Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology (2001) 95(1):241–249.
  • ALGOS PHARMACEUTICAL CORPORATION: Algos Pharmaceutical Corporation announces additional Phase III clinical trial data for its lead product MorphiDex. (September 1998) (Media Release).
  • ENDO PHARMACEUTICALS HOLDINGS INC: Endo Pharmaceuticals announces results from MorphiDex(R) Phase III clinical trial. (24 Jun 2002) (Media Release).
  • MONCK N: EN-3231. Endo Pharmaceuticals. Curr. Opin. Investig. Drugs (2002) 3(3):459–462.
  • HEISKANEN T, HARTEL B, DAHL ML et al.: Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain (2002) 96(3):261–267.
  • EISENBERG E, KLEISER A, DORTORT A, HAIM T, YARNITSKY D: The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur: .1 Pain (1998) 2(4):321–327.
  • SANG CN, BOOHER S, GILRON I, PARADA S, MAX MB: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology (2002) 96(5):1053–1061.
  • WIECH K, TOEPFNER S, KIEFER R et al.: Preventive and treatment effects of the NMDA-receptor antagonist memantine on phantom limb pain. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 103).
  • NIKOLAJSEN L, GOTTRUP H, KRISTENSEN AG, JENSEN TS: Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth. Analg. (2000) 91(4)960–966.
  • ROTHER E, GLASER A, BLEICH S, DEGNER D, WILTFANG J: A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiamy (2000) 33(3):103–108.
  • WALTERS MR, BRADFORD AP, FISCHER J, LEES KR: Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br. Clin. Pharmacol (2002) 53(3):305–311.
  • IYENGAR S, SANG CN, WEBSTER AA, SIMMONS RMA, RAMADAN NM: LY293558, an ampa/glur5 glutamate receptor antagonist is effective in animal and human models of neuropathic pain. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 611).
  • SANG CN, HOSTETTER MP, GRACELY RH et al.: AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology (1998) 89(5):1060–1067.
  • GILRON I, MAX MB, LEE G, BOOHER SL et al.: Effects of the 2-amino-3-hydroxy-5-methy1-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol Ther. (2000) 68(3)320–327.
  • SINDRUP SH, JENSEN TS: Antidepressants in the treatment of neuropathic pain. In: Neuropathic Pain: Pathophysiology and Treatment. PT Hansson, HL Fields, RG Hill, P Marchettini (Eds), IASP Press, Seattle, WA, USA (2001):169–184.
  • FIELDS HL, BAUSBAUM Al: Endogenous pain control mechanisms. In: Textbook of Pain. PD Wall, R Melzack (Eds), Churchill Livingstone, London (1984):142–152.
  • BYMASTER FP, DRESHFIELD-AHMAD LJ, THRELKELD PG et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters M vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology (2001) 25(6):871–880.
  • SINDRUP SH, BACH FW, MADSEN C, JENSEN TS: Venlafaxine Compared to Imipramine in Painful Polyneuropathy. American Pad) Society Annual Meeting, Baltimore, MD, USA (2002) (Abstract 767).
  • TASMUTH T, HARTEL B, KALSO E: Venlafaxine in neuropathic pain following treatment of breast cancer. Ear: Pad) (2002) 6(1):17–24.
  • FORSELL H, TASMUTH T, TENOVUO O, HAMPF G, KALSO E: Venlafaxine in the treatment of the atypical facial pain. International Association for the Study of Pad), 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 1253).
  • ANTTILA S, LEINONEN E: Duloxetine Eli Lilly. Carr: Opin. Investig. Drugs (2002) 3(8):1217–1221.
  • IYENGAR S, LEE DH, SIMMONS RMA: Duloxetine, a potent and selective dual serotonin-norepinephrine reuptake inhibitor, reverses mechanical allodynia behavior in rat models of neuropathic pain. American Pad) Society Annual Meeting, Phoenix, AZ, USA (2001) (Abstract 773).
  • IYENGAR S, BYMASTER FP, WONG D, AHMED L, SIMMONS RMA: Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. American Pad) Society Annual Meeting, Baltimore, MD, USA (2002) (Abstract 726).
  • GOLDSTEIN DJ, IYENGAR S, MALLINCKRODT C, LU Y, DETKE M, DEMITRACK MA: Duloxetine: a potential new treatment for depressed patients with comorbid pain. American Pain Socieg, Annual Meeting, Baltimore, MD, USA (2002) (Abstracts 789).
  • ROGERS BC: Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Neurotoxicology (1996) 17(3-4):865–870.
  • GORDON B: Bio-Technology General to buy Myelos. The Jerusalem Post. (25 Febuary 2001) (Internet Edition).
  • CADMAN J: Set back for nerve growth factor. GMHC Treat. Issues (1998) 12(9):12.
  • APFEL SC, SCHWARTZ S, ADORNATO BT et al.: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy a randomized controlled trial. The rhNGF Clinical Investigator Group. JA/VIA (2000) 284:2215–2221.
  • PETTY BG, CORNBLATH DR, ADORNATO BT et al: The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol (1994) 36:244–246.
  • MCARTHUR JC, YIANNOUTSOS C, SIMPSON DM et al.: A Phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology (2000) 54:1080–1088.
  • BALLET S, AUBEL B, MAUBORGNE A et al.: The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology (2001) 40(4):578–589.
  • SHEMBALKAR P, TAUBEL J, ABADIAS M et al.: Cizolirtine citrate (E-4018) in the treatment of chronic neuropathic pain. Carr. Med. Res. Opin. (2001) 17(4):262–266.
  • ISHIKAWA H, MITSUI Y, YOSHITOMI T et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. fpn. Ophthalmol (2000) 44(2):106–109.
  • SILBERSTEIN SD: Review of botulinumtoxin type A and its clinical applications in migraine headache. Expert Opin. Pharmacother. (2001) 2(10):1649–1654.
  • FOSTER L, CLAPP L, ERICKSON M, JABBARI B: Botufinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology (2001) 56(10):1290–1293.
  • NIXDORF D, HEO G, MAJOR P: Randomized controlled trial of botulinum toxin for chronic myogenous orofacial pain. International Association for the Study of Pad), 10th World Congress on Pad), San Diego, CA, USA (2002) (Abstract 612).
  • NALAMACHU S, SIMON S: A prospective double-blind randomised, placebo-controlled trial of botulinum toxin type b for the treatment of fibromyalgia syndrome. International Association for the Study of Pain, 10th World Congress on Pad), San Diego, CA, USA (2002) (Abstract 1337).
  • PRICE DD, VON DER GRUEN A, MILLER J, RAFII A & PRICE C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist._Anesth. Analg. (1985) 64:801–806.
  • MCCLEANE GJ: The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesth. Analg. (1998) 87:1117–1120.
  • MCCLEANE G: A cholecystokinin receptor antagonist proglumide enhances the analgesic effect of dihydrocodeine. American Pad) Socieg, Annual Meeting, Baltimore, MD, USA (2002) (Abstract 792).
  • SIMPSON KH, SERPELL M, MCCUBBINS TD et al: A multi-dose study: Management of neuropathic pain in patients using a CCK antagonist Devazepide (DEVACADE) as an adjunct to strong opioids. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA. (2002) (1443 Mini-Symposium).
  • MCCLEANE G: A study of the cck-b antagonist L 365,260 in human subjects taking morphine for chronic neuropathic pain. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 1289).

Websites

  • http://www.partnersagainstpain.com/html/ pat_care/pat_care.htm? pg=6343&section=pat_care GALLUP SURVEY HIGHLIGHTS: Pain in America (2000). Partners Against Pain Site.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.